Financial Consulate’s Protagonist Therapeutics PTGX Stock Holding History

Financial Consulate’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$564	Buy	+4	New	+$570	﹤0.01%	1438

Other funds holding PTGX

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Franklin Street Advisors Chapel Hill, North Carolina $1.82B AUM 22.19% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Financial Consulate's PTGX Position: Q3 2026 in Review

Financial Consulate opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 4 shares worth $564. The stake represents ﹤0.01% of the portfolio and ranks #1438 among its holdings.

56 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

Financial Consulate held 4 shares of Protagonist Therapeutics worth $564 as of Q3 2026.
Protagonist Therapeutics was a new Financial Consulate position in Q3 2026.
Protagonist Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1438 holding.
56 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.